Chinese vaccine makers sign COVAX agreements

Gavi, the vaccine partnership playing a leading role in COVAX, announced that it would buy 110 million doses from Sinopharm and Sinovac between now and October. In addition, it has the option to buy 440 million more doses by mid-2022.

Agencies
China's two major COVID-19 vaccine makers have signed agreements to provide up to 550 million doses to COVAX, the UN-backed program that aims to deliver vaccines to poor countries and others that need them.

Gavi, the vaccine partnership playing a leading role in COVAX, announced that it would buy 110 million doses from Sinopharm and Sinovac between now and October. In addition, it has the option to buy 440 million more doses by mid-2022.

The World Health Organization has approved the companies' vaccines for emergency use. Their inactivated vaccines are already in widespread use in China and in many other countries.


Inactivated vaccines are made with killed coronavirus. Most other COVID vaccines in use, particularly in the West, are made with newer technologies that target the “spike” protein that coats the surface of the virus.
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › News › International › World News › Chinese vaccine makers sign COVAX agreements
Text Size:AAA
Success
This article has been saved

*

+